{"id":15982,"date":"2020-10-08T11:46:16","date_gmt":"2020-10-08T11:46:16","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=15982"},"modified":"2021-03-25T12:02:05","modified_gmt":"2021-03-25T12:02:05","slug":"us-adult-illicit-cannabis-use-cannabis-use-disorder-and-medical-marijuana-laws","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2020\/10\/us-adult-illicit-cannabis-use-cannabis-use-disorder-and-medical-marijuana-laws\/","title":{"rendered":"US Adult Illicit Cannabis Use, Cannabis Use Disorder, And Medical Marijuana Laws"},"content":{"rendered":"

Question<\/strong>\u00a0\u00a0Are US state medical marijuana laws one of the underlying factors for increases in risk for adult cannabis use and cannabis use disorders seen since the early 1990s?<\/span><\/p>\n

Findings<\/strong>\u00a0\u00a0In this analysis using US national survey data collected in 1991-1992, 2001-2002, and 2012-2013 from 118\u202f497 participants, the risk for cannabis use and cannabis use disorders increased at a significantly greater rate in states that passed medical marijuana laws than in states that did not.<\/span><\/p>\n

Meaning<\/strong>\u00a0\u00a0Possible adverse consequences of illicit cannabis use due to more permissive state cannabis laws should receive consideration by voters, legislators, and policy and health care professionals, with appropriate health care planning as such laws change.<\/span><\/p>\n

\n
Abstract<\/strong><\/span><\/div>\n
<\/div>\n<\/div>\n

Importance<\/strong>\u00a0\u00a0Over the last 25 years, illicit cannabis use and cannabis use disorders have increased among US adults, and 28 states have passed medical marijuana laws (MML). Little is known about MML and adult illicit cannabis use or cannabis use disorders considered over time.<\/span><\/p>\n

Objective<\/strong>\u00a0\u00a0To present national data on state MML and degree of change in the prevalence of cannabis use and disorders.<\/span><\/p>\n

Design, Participants, and Setting<\/strong>\u00a0\u00a0Differences in the degree of change between those living in MML states and other states were examined using 3 cross-sectional US adult surveys: the National Longitudinal Alcohol Epidemiologic Survey (NLAES; 1991-1992), the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; 2001-2002), and the National Epidemiologic Survey on Alcohol and Related Conditions\u2013III (NESARC-III; 2012-2013). Early-MML states passed MML between NLAES and NESARC (\u201cearlier period\u201d). Late-MML states passed MML between NESARC and NESARC-III (\u201clater period\u201d).<\/span><\/p>\n

Main Outcomes and Measures<\/strong>\u00a0\u00a0Past-year illicit cannabis use and\u00a0DSM<\/i>–IV<\/i>\u00a0cannabis use disorder.<\/span><\/p>\n

Results<\/strong>\u00a0\u00a0Overall, from 1991-1992 to 2012-2013, illicit cannabis use increased significantly more in states that passed MML than in other states (1.4\u2013percentage point more; SE, 0.5;\u00a0P<\/i>\u2009=\u2009.004), as did cannabis use disorders (0.7\u2013percentage point more; SE, 0.3;\u00a0P<\/i>\u2009=\u2009.03). In the earlier period, illicit cannabis use and disorders decreased similarly in non-MML states and in California (where prevalence was much higher to start with). In contrast, in remaining early-MML states, the prevalence of use and disorders increased. Remaining early-MML and non-MML states differed significantly for use (by 2.5 percentage points; SE, 0.9;\u00a0P<\/i>\u2009=\u2009.004) and disorder (1.1 percentage points; SE, 0.5;\u00a0P<\/i>\u2009=\u2009.02). In the later period, illicit use increased by the following percentage points: never-MML states, 3.5 (SE, 0.5); California, 5.3 (SE, 1.0); Colorado, 7.0 (SE, 1.6); other early-MML states, 2.6 (SE, 0.9); and late-MML states, 5.1 (SE, 0.8). Compared with never-MML states, increases in use were significantly greater in late-MML states (1.6\u2013percentage point more; SE, 0.6;\u00a0P<\/i>\u2009=\u2009.01), California (1.8\u2013percentage point more; SE, 0.9;\u00a0P<\/i>\u2009=\u2009.04), and Colorado (3.5\u2013percentage point more; SE, 1.5;\u00a0P<\/i>\u2009=\u2009.03). Increases in cannabis use disorder, which was less prevalent, were smaller but followed similar patterns descriptively, with change greater than never-MML states in California (1.0\u2013percentage point more; SE, 0.5;\u00a0P<\/i>\u2009=\u2009.06) and Colorado (1.6\u2013percentage point more; SE, 0.8;\u00a0P<\/i>\u2009=\u2009.04).<\/span><\/p>\n

Conclusions and Relevance<\/strong>\u00a0\u00a0Medical marijuana laws appear to have contributed to increased prevalence of illicit cannabis use and cannabis use disorders. State-specific policy changes may also have played a role. While medical marijuana may help some, cannabis-related health consequences associated with changes in state marijuana laws should receive consideration by health care professionals and the public.<\/span><\/p>\n

Source: https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/article-abstract\/2619522<\/a> June 2017<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Question\u00a0\u00a0Are US state medical marijuana laws one of the underlying factors for increases in risk for adult cannabis use and cannabis use disorders seen since the early 1990s? Findings\u00a0\u00a0In this analysis using US national survey data collected in 1991-1992, 2001-2002, and 2012-2013 from 118\u202f497 participants, the risk for cannabis use and cannabis use disorders increased […]<\/p>\n","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68,12,60],"tags":[],"class_list":["post-15982","post","type-post","status-publish","format-standard","hentry","category-drug-use-various-effects","category-legal-sector","category-marijuana-and-medicine"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/15982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=15982"}],"version-history":[{"count":0,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/15982\/revisions"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=15982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=15982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=15982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}